SEATTLE, WA, March 29 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the Company will be presenting at the following scientific & investor conferences during April:
American Association of Cancer Research 102nd Annual Conference
Preclinical data about ONT-10, Oncothyreon's proprietary, follow-on cancer vaccine, and PX-866, the Company's irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), will be highlighted in the following poster presentations:
ONT-10, a liposomal vaccine targeting hypoglycosylated MUC1, induces a potent cellular and humoral response and suppresses the growth of MUC1 expressing tumors
- Abstract number: 762
- Presenter: Scott Peterson, Ph.D, Vice President, Research & Development, Oncothyreon
- Presentation Time: Sunday, April 3, 1:00-5:00 p.m. EDT
- Location: Exhibit Hall A4-C, Poster Section 31
PI3K inhibition combined with either cetuximab or docetaxel in a direct patient tumor model of HPV-positive and negative head and neck cancers
- Abstract Number: 652
- Presenter: Antonio Jimeno, M.D., Ph.D., of the University of Colorado Cancer Center
- Presentation Time: Sunday, April 03, 2011, 1:00 - 5:00 p.m. EDT
- Location: Exhibit Hall A4-C, Poster Section 27
10th Annual Needham Healthcare Conference
Robert Kirkman, M.D., Oncothyreon's President and Chief Executive Officer, will present at the Needham Conference in New York on Wednesday, April 6 at 10:40 a.m. EDT. A live and archived webcast of the corporate presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.
Leerink Swann Cancer Roundtable Conference
Dr. Kirkman will participate on an immunotherapy panel, moderated by Leerink Swann analysts and including other immunotherapy company executives, during this conference in New York. Dr. Kirkman's panel is scheduled for Thursday, April 7 at 8:00 a.m. EDT.
World Vaccine Congress 2011
Dr. Peterson will give an oral presentation at the World Vaccine Congress in Washington D.C. on Thursday, April 14 at 9:40 a.m. EDT. Dr. Peterson's presentation titled "Liposome Vaccines Designed to Induce Immune Response to Cancer Cells Expressing MUC1" will highlight preclinical data on ONT-10.
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov. and in Canada on SEDAR.
SOURCE Oncothyreon Inc.